Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT™)
“Since the inception of our technology, our scientists have been focused on the design and delivery of mRNA as a therapeutic and on building our intellectual property to support our discoveries,” said
This newly granted patent is part of an expanding and comprehensive portfolio of patent applications and other intellectual property supporting Translate Bio’s messenger RNA therapeutics (MRTTM) platform, and particularly its MRT liver delivery system. The Company’s intellectual property portfolio is comprised of significant patents and patent applications supporting mRNA biology and manufacturing, as well as multiple delivery systems, which the Company believes are important for the development and commercialization of a wide range of mRNA therapeutics. In aggregate,
About the MRTTM Platform
Translate Bio’s MRT platform is designed to develop product candidates that deliver mRNA that can carry instructions to produce intracellular, transmembrane and secreted proteins. The MRT platform is also designed to be flexible and scalable by allowing for the development of MRT product candidates that may vary only in the mRNA coding sequence and/or the tissue-specific delivery system. This modular nature of the MRT platform may allow for rapid advancement into new indications that are amenable to our established delivery systems. Currently, the Company is utilizing its MRT platform to identify and rapidly develop new product candidates designed to address the underlying causes of diseases beyond our initial efforts in the lung, to treat cystic fibrosis, and in the liver, to treat OTC deficiency.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: Translate Bio’s expectations regarding the potential for its patent portfolio to protect its intellectual property; the benefits and broad applicability of the Company’s MRTTM platform; and Translate Bio’s plans, strategies and prospects for its business, including its lead development programs. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Translate Bio’s ability to advance the development of its platform and programs under the timelines it projects, demonstrate the requisite safety and efficacy of its product candidates and replicate in clinical trials any positive findings from preclinical studies; Translate Bio’s ability to enroll patients in its ongoing clinical trial; the content and timing of decisions made by the
|Teri Dahlman||Maura Gavaghan|
Source: Translate Bio, Inc.